In a swift resolution that underscores the pharmaceutical industry’s preference for negotiated outcomes over protracted litigation, Impax Laboratories, LLC and Ascent Pharmaceuticals Inc. reached an apparent settlement in Case No. 1:24-cv-05299 before the U.S. District Court for the District of New Jersey. Filed on April 18, 2024, and administratively terminated on August 26, 2024—just 130 days later—the infringement action centered on eight U.S. patents covering the extended-release carbidopa/levodopa formulation commercialized as RYTARY®, a key treatment for Parkinson’s disease. The court’s termination order left 60 days for the parties to file dismissal papers or risk a with-prejudice dismissal.

For patent attorneys, in-house IP teams, and R&D leaders operating in the branded pharmaceutical space, this case highlights the strategic weight of multi-patent portfolios in deterring generic entry. With eight patents spanning multiple application families—including US8557283B2, US9463246B2, and US9901640B2—Impax constructed a layered exclusivity position around RYTARY® that likely shaped Ascent’s calculus at the negotiating table. Understanding the claim scope and prosecution history of each asserted patent is critical for any company developing extended-release drug delivery formulations in this competitive therapeutic category.

Case Overview

The Parties

The Patents at Issue

The eight patents asserted in this case—US8557283B2, US9463246B2, US8377474B2, US8454998B2, US9089608B2, US9089607B2, US9533046B2, and US9901640B2—collectively cover the extended-release formulation technology underlying RYTARY® (carbidopa/levodopa), a drug used to manage the motor symptoms of Parkinson’s disease. These patents protect various aspects of the pharmaceutical composition, including specific bead formulations, release-rate profiles, and methods of administration designed to provide more sustained therapeutic levels compared to immediate-release alternatives. Together, they form a multi-layered exclusivity wall that makes designing around any single patent insufficient for a generic entrant to achieve freedom to operate.

• • US8557283B2
• • US9463246B2
• • US8377474B2
• • US8454998B2
• • US9089608B2
• • US9089607B2
• • US9533046B2
• • US9901640B2

Legal Representation

Plaintiff Counsel: Troutman Pepper Hamilton Sanders LLP (lead: Stephanie L. Jonaitis)
Defendant Counsel: Hill Wallack LLP (lead: Eric I. Abraham)

Litigation Timeline & Procedural History

The case was filed in the U.S. District Court for the District of New Jersey, one of the most patent-litigation-active venues in the country and a preferred forum for Hatch-Waxman ANDA disputes due to its experienced judiciary and well-developed local patent rules. As a first-instance district court proceeding, this matter was positioned for full merits adjudication—including claim construction, infringement analysis, and potential validity challenges—before the parties chose an alternative path. The New Jersey District Court regularly handles high-stakes pharmaceutical patent cases, giving it significant institutional expertise in the complex scientific and legal questions that arise in extended-release formulation disputes.

At just 130 days from filing to administrative termination, this case resolved with exceptional speed relative to the typical multi-year lifecycle of Hatch-Waxman litigation. The court’s August 26, 2024 order administratively terminated the action without constituting a formal dismissal under Federal Rule of Civil Procedure 41, granting the parties a 60-day window to either file dismissal papers or request the action be reopened if settlement could not be consummated. This procedural mechanism—a common tool in New Jersey federal practice—strongly signals that the parties had reached, or were very close to reaching, a settlement agreement, though the specific terms of any such agreement were not disclosed in the public record.

The Verdict & Legal Analysis

Outcome

The District Court for the District of New Jersey administratively terminated Case No. 1:24-cv-05299 on August 26, 2024, without issuing a merits ruling on infringement, validity, or enforceability of any of the eight asserted RYTARY® patents. No damages award, injunctive relief, or cost allocation was ordered, as the case was resolved through what the procedural record strongly suggests was a confidential settlement between Impax Laboratories and Ascent Pharmaceuticals. Absent submission of dismissal papers or a motion to reopen within 60 days of the termination order, the court indicated it would dismiss the action with prejudice and without costs.

Verdict Cause Analysis

The infringement action brought by Impax Laboratories against Ascent Pharmaceuticals rested on several interrelated legal and strategic grounds characteristic of multi-patent Hatch-Waxman enforcement.

• Impax asserted all eight U.S. patents covering RYTARY®’s extended-release formulation, creating a broad infringement claim that would require Ascent to successfully challenge or design around every patent to proceed with its generic launch.
• The administrative termination order, entered just 130 days after filing, was expressly distinguished from a dismissal under FRCP 41, signaling a structured settlement process rather than a unilateral withdrawal or adverse ruling.
• The court’s 60-day window for filing dismissal papers or requesting reopening is a standard New Jersey District Court mechanism used when parties have reached a settlement in principle but require additional time to finalize and document the agreement.
• No public record of a preliminary injunction motion or early dispositive motion suggests the parties engaged in settlement discussions relatively early in the litigation, possibly facilitated by the strength of Impax’s layered patent portfolio.

Legal Significance

1. The rapid 130-day resolution of an eight-patent pharmaceutical infringement action reinforces that a robust, multi-patent exclusivity portfolio can function as a powerful deterrent, prompting settlement before significant litigation costs are incurred by either party.
2. The court’s use of administrative termination rather than a FRCP 41 dismissal preserves the court’s jurisdiction and the parties’ ability to reopen the action, which is a meaningful procedural distinction that practitioners should recognize as indicative of a settlement in progress rather than a conceded or abandoned claim.
3. Cases of this nature in the New Jersey District Court—involving stacked patent families covering a branded pharmaceutical product—continue to demonstrate that generic manufacturers face compounding invalidity and non-infringement burdens when a brand holder has prosecuted overlapping claims across multiple patent applications, a strategy increasingly scrutinized for potential obviousness-type double patenting issues.

Strategic Takeaways

For Patent Attorneys:

• When defending an ANDA-related infringement suit involving multiple patents, file early invalidity contentions and inter partes review petitions strategically to fracture the brand holder’s portfolio and create settlement leverage before the case reaches claim construction.
• The administrative termination mechanism used here—distinct from a FRCP 41 dismissal—should be understood as preserving court jurisdiction; practitioners should negotiate clear reopening and dismissal deadlines in any settlement term sheet to avoid inadvertent with-prejudice dismissal.
• For brand-side patent counsel, Impax’s eight-patent assertion strategy across multiple application families (spanning application numbers US12/599668 through US15/382851) illustrates the value of building continuation and divisional applications to create overlapping claim coverage that complicates a single design-around approach.

For IP Professionals:

• Monitor the USPTO assignment database and any forthcoming dismissal filings in Case No. 1:24-cv-05299 to identify whether the settlement included a licensing agreement or authorized generic arrangement that could affect RYTARY®’s exclusivity landscape.
• Conduct a patent family mapping exercise across all eight asserted patents to identify expiration cliffs and any potential post-grant review vulnerability, as the portfolio spans multiple priority chains from at least 2009 through 2015 filing dates.

For R&D Teams:

• Any R&D team developing carbidopa/levodopa extended-release formulations or analogous multi-bead delivery systems should commission a freedom-to-operate analysis covering all eight RYTARY® patents before initiating ANDA filings or NDA submissions to assess infringement exposure across the full claim landscape.
• The settlement outcome—without a validity ruling—means all eight patents remain in force, and competing formulators cannot rely on potential invalidity as a risk mitigation strategy; design-around efforts must address each patent’s independent claims individually.